Esopraid D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), acid reflux, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), selectively inhibits the H+/K+ ATPase enzyme system in the gastric parietal cells, leading to a significant and prolonged reduction in gastric acid secretion. The sustained-release (SR) formulation ensures a gradual and consistent release of active ingredients, optimizing therapeutic efficacy and improving patient compliance. Esopraid D Capsule SR is indicated for patients with erosive esophagitis, non-erosive reflux disease, and Zollinger-Ellison syndrome, as well as for the prevention of acid-related damage to the esophageal mucosa. It should be used under medical supervision, with caution advised in patients with hepatic impairment or known hypersensitivity to its components. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. This combination therapy offers a dual mechanism approach, addressing both acid suppression and motility enhancement for comprehensive symptom relief.